EP3218412 - METHODS FOR TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 14.03.2019 Database last updated on 24.08.2024 | |
Former | Request for examination was made Status updated on 18.08.2017 | ||
Former | The international publication has been made Status updated on 15.06.2017 | Most recent event Tooltip | 02.10.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Sanofi Biotechnology 54 rue La Boétie 75008 Paris / FR | For all designated states Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | [2017/38] | Inventor(s) | 01 /
MANNENT, Leda c/o Sanofi 54 Rue La Boetie F-75008 Paris / FR | 02 /
PIROZZI, Gianluca c/o Sanofi U.S 55 Corporate Drive Mail Code: 55A-505A Bridgewater, NJ 08807 / US | 03 /
SWANSON, Brian N. c/o Sanofi U.S 55 Corporate Drive Mail Code: 55A-505A Bridgewater, NJ 08807 / US | 04 /
RADIN, Allen c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | 05 /
GANDHI, Namita A. c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | 06 /
EVANS, Robert c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | 07 /
HAMILTON, Jennifer Davidson C/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | [2017/38] | Representative(s) | Zwicker, Jörk ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [N/P] |
Former [2017/38] | Rai, Monika, et al Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB | Application number, filing date | 15804646.6 | 13.11.2015 | [2017/38] | WO2015US60540 | Priority number, date | US201462080092P | 14.11.2014 Original published format: US 201462080092 P | US201462083821P | 24.11.2014 Original published format: US 201462083821 P | US201562158832P | 08.05.2015 Original published format: US 201562158832 P | US201562199305P | 31.07.2015 Original published format: US 201562199305 P | EP20150306632 | 14.10.2015 Original published format: EP 15306632 | [2017/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016077675 | Date: | 19.05.2016 | Language: | EN | [2016/20] | Type: | A1 Application with search report | No.: | EP3218412 | Date: | 20.09.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.05.2016 takes the place of the publication of the European patent application. | [2017/38] | Search report(s) | International search report - published on: | EP | 19.05.2016 | Classification | IPC: | C07K16/28, A61K39/395, A61K39/00 | [2017/38] | CPC: |
C07K16/2866 (EP,CN,IL,KR,RU,US);
A61B5/4848 (EP,IL,KR,RU,US);
A61K31/573 (IL,RU,US);
A61K31/58 (EP,IL,RU,US);
A61K39/3955 (EP,IL,RU,US);
A61K9/0043 (IL,RU,US);
A61P11/02 (EP,IL,KR,RU);
A61P11/06 (EP,IL,KR,RU);
A61P37/06 (EP,IL,KR,RU);
A61P37/08 (EP,IL,KR,RU);
A61P7/00 (EP,IL,RU);
A61K2039/505 (EP,CN,IL,KR,US);
A61K2039/54 (EP,IL,KR,US);
A61K2039/545 (EP,CN,IL,KR,US);
C07K2317/21 (EP,CN,IL,KR,US);
C07K2317/76 (EP,CN,IL,KR,US)
(-)
| C-Set: |
A61K31/58, A61K2300/00 (US,EP);
A61K39/3955, A61K2300/00 (EP,US) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/38] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON CHRONISCHER SINUSITIS MIT NASENPOLYPEN DURCH VERABREICHUNG EINES IL-4R-ANTAGONISTEN | [2017/38] | English: | METHODS FOR TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST | [2017/38] | French: | MÉTHODES DE TRAITEMENT DE LA SINUSITE CHRONIQUE AVEC POLYPOSE NASALE PAR ADMINISTRATION D'UN ANTAGONISTE D'IL-4R | [2017/38] | Entry into regional phase | 13.06.2017 | National basic fee paid | 13.06.2017 | Designation fee(s) paid | 13.06.2017 | Examination fee paid | Examination procedure | 13.06.2017 | Amendment by applicant (claims and/or description) | 13.06.2017 | Examination requested [2017/38] | 13.06.2017 | Date on which the examining division has become responsible | 18.03.2019 | Despatch of a communication from the examining division (Time limit: M06) | 30.09.2019 | Reply to a communication from the examining division | 21.04.2020 | Despatch of a communication from the examining division (Time limit: M04) | 21.08.2020 | Reply to a communication from the examining division | 19.10.2022 | Despatch of a communication from the examining division (Time limit: M06) | 21.04.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 13.11.2017 | Renewal fee patent year 03 | 14.11.2018 | Renewal fee patent year 04 | 14.11.2019 | Renewal fee patent year 05 | 13.11.2020 | Renewal fee patent year 06 | 19.10.2021 | Renewal fee patent year 07 | 13.10.2022 | Renewal fee patent year 08 | 29.09.2023 | Renewal fee patent year 09 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2014072583 (ARDELEANU MARIUS [US], et al) [A] 1-154 * page 56, paragraph 0477 - page 57, paragraph 0478 ** sequences 162, 164 *; | [XP]WO2014205365 (SANOFI SA [FR], et al) [XP] 1-154 * the whole document *; | [XI] - Anonymous, "Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps", (20140930), URL: http://files.shareholder.com/downloads/REGN/0x0x783968/ea1617b5-cd39-46c9-a619-2bdb378cc8d0/REGN_News_2014_9_30_General_Releases.pdf, (20160112), XP055240175 [X] 1,3-8,10-22,24-29,31-41,43-48,50,51,54-78,80-85,87-99,101-106,108-118,120-125,127,128,131-154 * page 1, paragraph 1 - paragraph 5 * [I] 2,9,23,30,42,49,52,53,79,86,100,107,119,126,129,130 | [A] - "International Nonproprietary Names for Pharmaceutical Substances (INN) Dénominations communes internationales des Substances pharmaceutiques (DCI)", WHO Drug Information, (20120101), URL: http://www.who.int/medicines/publications/druginformation/issues/PL_108.pdf, (20160113), XP055084074 [A] 1-154 * page 412 * | [A] - Anonymous, "CAS: PubChem: DRUG D10354-Dupilumab", (20140214), URL: http://www.genome.jp/dbget-bin/www_bget?dr:D10354, (20160112), XP055240675 [A] 1-154 * the whole document * | [A] - Anonymous, "PubChem SID 172232447", (20140214), URL: http://pubchem.ncbi.nlm.nih.gov/substance/172232447#section=Top, (20160112), XP055240678 [A] 1-154 * the whole document * | [AP] - Anonymous, "Alignment Heavy Chain dupilumab with SEQ ID NO 9", (20160112), URL: http://blast.ncbi.nlm.nih.gov/Blast.cgi, (20160112), XP055240680 [AP] 1-154 * the whole document * | [AP] - Anonymous, "Alignment of light chain of dupilumab with SEQ ID No 10", (20160112), URL: http://blast.ncbi.nlm.nih.gov/Blast.cgi, (20160112), XP055240683 [AP] 1-154 * the whole document * | by applicant | US6927044 | US7186809 | US7582298 | US7605237 | US7608693 | US8092804 | - HOPKINS ET AL., CLIN. OTOLARYNGOL., (2009), vol. 34, pages 447 - 454 | - TAYLOR ET AL., NUCL. ACIDS RES., (1992), vol. 20, pages 6287 - 6295 | - CORREN ET AL., AM J RESPIR CRIT CARE MED., (2010), vol. 181, no. 8, pages 788 - 796 | - GENNARO, Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY | - POWELL ET AL., "Compendium of excipients for parenteral formulations", PDA (1998) J PHARM SCI TECHNOL, (1998), vol. 52, pages 238 - 311 | - MORDENTI ET AL., PHARMACEUT. RES., (1991), vol. 8, page 1351 | - WU ET AL., J. BIOL. CHEM., (1987), vol. 262, pages 4429 - 4432 | - SEFTON, CRC CRIT. REF. BIOMED. ENG., (1987), vol. 14, page 201 | - GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, (1984), vol. 2, pages 115 - 138 | - LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533 |